News | March 04, 2021
Merck FY20 sales up 8.6% euro 17.5 bn
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
ekincare has raised a total funding of $22M since 2015 till date
Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations
Subscribe To Our Newsletter & Stay Updated
